Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573702 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT01573702 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 32 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT01573702, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
\- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
Conditions Studied
Interventions
- PROCEDURE Stereotactic Radiosurgery
- DRUG Erlotinib
Study Locations (8)
North Carolina
- Lineberger Comprehensive Cancer Center - Chapel Hill
- East Carolina University - Greenville
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- University of California at San Francisco - San Francisco
Colorado
- University of Colorado Cancer Center - Aurora
Ohio
- STO Taussig Cancer Center; Cleveland Clinic - Cleveland
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2012-12-11 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573702
The ClinicalTrials.gov registry entry for NCT01573702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Radiosurgery is the first listed.
NCT01573702 reports 8 study locations spanning 6 distinct geographic areas - top geographies include North Carolina, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT01573702 about?
NCT01573702 is a clinical study titled "Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)". \- Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
What is the current status of trial NCT01573702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2012-12-11. Estimated completion is 2019-03-15.
What conditions does trial NCT01573702 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT01573702?
The interventions under investigation include: Stereotactic Radiosurgery (PROCEDURE), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01573702?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01573702 being conducted?
This trial has 8 study locations across California, Colorado, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.